生物科技公司卡迪根（KARD）今日盘中大涨5.44%，引起了市场的广泛关注。
消息面上，卡迪根成功完成了规模扩大的首次公开募股（IPO），以每股16美元的价格发行2500万股，共筹集4亿美元资金，发行价位于目标区间上限。该公司股票于今日在纳斯达克交易所首次上市交易，市场对其首日表现抱有较高期待。
卡迪根是一家专注于心血管疾病药物研发的临床阶段生物技术公司，目前正在推进三项处于后期临床试验阶段的疗法，包括用于治疗遗传性扩张型心肌病的danicamtiv、用于治疗主动脉瓣钙化性狭窄的ataciguat以及针对急性重度高血压的tonlamarsen。公司计划将本次IPO募集资金用于这些药物的临床开发及其他研发活动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.